References
- 1. 1. Iorga RA, Bratu OG, Marcu RD, et al. Venous thromboembolism in cancer patients: Still looking for answers. Exp Ther Med. 2019;18(6):5026-5032. doi:10.3892/etm.2019.801910.3892/etm.2019.8019
- 2. 2. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891-1894. doi:10.1111/jth.1421910.1111/jth.14219
- 3. 3.Streiff MB, Holmstrom B, Angelini D, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289-1303. doi:10.6004/jnccn.2018.008410.6004/jnccn.2018.0084
- 4. 4. Trujillo-Santos J, Casas JM, Casado I, et al.RIETE Investigators. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res. 2011 Feb;127 Suppl 3:S1-4.10.1016/S0049-3848(11)00006-5
- 5. 5. Horowitz NA, Brenner B. Thrombosis in hematological malignancies: mechanisms and implications. Thromb Res. 2020 Jul;191 Suppl 1:S58-S62.10.1016/S0049-3848(20)30398-4
- 6. 6. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. doi:10.1182/blood-2002-01-010810.1182/blood-2002-01-0108
- 7. 7. Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020;136(12):1433-1441. doi:10.1182/blood.202000581910.1182/blood.2020005819
- 8. 8. Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol. 2017;10(1):15-22. doi:10.1080 /17474086.2017.125793510.1080/17474086.2017.1257935
- 9. 9. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz40510.1093/eurheartj/ehz405